<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Dyne Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/dyne-therapeutics-inc</link>
<description>Latest news and press releases for Dyne Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 20:34:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/dyne-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835608878dffbe2df0ee0c7.webp</url>
<title>Dyne Therapeutics Inc</title>
<link>https://6ix.com/company/dyne-therapeutics-inc</link>
</image>
<item>
<title>Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-upcoming-presentation-highlighting-robust-cns-activity-in-nonhuman-primates-with-its-forcetm-platform-at-2026-asgct-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-upcoming-presentation-highlighting-robust-cns-activity-in-nonhuman-primates-with-its-forcetm-platform-at-2026-asgct-annual-meeting</guid>
<pubDate>Mon, 27 Apr 2026 20:34:00 GMT</pubDate>
<description>- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier - WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present new preclinical data demonstrating the ability of the FORCE platform to cross the blood-brain barrier (BBB) and</description>
</item>
<item>
<title>Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-participation-at-2026-academy-of-managed-care-pharmacy-amcp-conference-to-begin-shaping-access-in-us-for-potential-neuromuscular-medicines</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-participation-at-2026-academy-of-managed-care-pharmacy-amcp-conference-to-begin-shaping-access-in-us-for-potential-neuromuscular-medicines</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of</description>
</item>
<item>
<title>Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-new-positive-cardiopulmonary-results-from-deliver-trial-of-z-rostudirsen-in-duchenne-muscular-dystrophy-dmd</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-new-positive-cardiopulmonary-results-from-deliver-trial-of-z-rostudirsen-in-duchenne-muscular-dystrophy-dmd</guid>
<pubDate>Sun, 08 Mar 2026 05:00:00 GMT</pubDate>
<description>- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on</description>
</item>
<item>
<title>Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-initiation-of-phase-3-harmonia-trial-of-z-basivarsen-in-myotonic-dystrophy-type-1-dm1</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-initiation-of-phase-3-harmonia-trial-of-z-basivarsen-in-myotonic-dystrophy-type-1-dm1</guid>
<pubDate>Sun, 08 Mar 2026 05:00:00 GMT</pubDate>
<description>- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150</description>
</item>
<item>
<title>Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Mon, 02 Mar 2026 12:30:00 GMT</pubDate>
<description>- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 skip amenable Duchenne muscular dystrophy (DMD); additional long-term data to be presented at MDA - - Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in myotonic dystrophy type 1 (DM1) expected in Q2 2026; Phase 3 trial design to be</description>
</item>
<item>
<title>Dyne Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Wed, 25 Feb 2026 12:30:00 GMT</pubDate>
<description>WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, fireside chat on Wednesday, March 4, 2026 at 11:50 a.m. ET in Boston, MA2026 Jefferies Biotech on the Beach Summit, hostin</description>
</item>
<item>
<title>Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-upcoming-presentations-across-neuromuscular-pipeline-at-2026-mda-clinical-and-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-upcoming-presentations-across-neuromuscular-pipeline-at-2026-mda-clinical-and-scientific-conference</guid>
<pubDate>Sun, 22 Feb 2026 05:00:00 GMT</pubDate>
<description>- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD - - Oral presentation on Phase</description>
</item>
<item>
<title>Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-receives-orphan-drug-123000925</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-receives-orphan-drug-123000925</guid>
<pubDate>Tue, 20 Jan 2026 12:30:00 GMT</pubDate>
<description>- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE Registrational Expansion Cohort in early Q2 2026 - WALTHAM, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that t</description>
</item>
<item>
<title>Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-present-44th-annual-123000938</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-present-44th-annual-123000938</guid>
<pubDate>Wed, 07 Jan 2026 12:30:00 GMT</pubDate>
<description>WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available in the Investor</description>
</item>
<item>
<title>Dyne Therapeutics Appoints Vikram Karnani to Board of Directors</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-appoints-vikram-karnani-board-directors-2025-12-23</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-appoints-vikram-karnani-board-directors-2025-12-23</guid>
<pubDate>Tue, 23 Dec 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement</description>
</item>
<item>
<title>Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-closing-upsized-public-offering-common-stock-and-full</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-closing-upsized-public-offering-common-stock-and-full</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement</description>
</item>
<item>
<title>Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-pricing-upsized-3500-million-public-offering-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-pricing-upsized-3500-million-public-offering-common-stock</guid>
<pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement</description>
</item>
<item>
<title>Dyne Therapeutics Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-proposed-public-offering-common-stock-2025-12-08</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-proposed-public-offering-common-stock-2025-12-08</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement</description>
</item>
<item>
<title>Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-positive-topline-results-phase-1-2-deliver-trial-z</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-positive-topline-results-phase-1-2-deliver-trial-z</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>- Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle</description>
</item>
<item>
<title>Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-host-investor-conference-call-and-webcast-review-topline-results</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-host-investor-conference-call-and-webcast-review-topline-results</guid>
<pubDate>Sun, 07 Dec 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement</description>
</item>
<item>
<title>Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for</description>
</item>
<item>
<title>Dyne Therapeutics to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-present-upcoming-investor-conferences-2025-11-03</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-present-upcoming-investor-conferences-2025-11-03</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement</description>
</item>
<item>
<title>Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-additional-one-year-clinical-data-demonstrating</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-announces-additional-one-year-clinical-data-demonstrating</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in</description>
</item>
<item>
<title>Dyne Therapeutics Appoints Brian Posner to its Board of Directors</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-appoints-brian-posner-its-board-directors-2025-10-02</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-appoints-brian-posner-its-board-directors-2025-10-02</guid>
<pubDate>Thu, 02 Oct 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement</description>
</item>
<item>
<title>Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-receives-orphan-drug-designation-japan-dyne-251-duchenne-muscular</link>
<guid isPermaLink="true">https://6ix.com/company/dyne-therapeutics-inc/news/dyne-therapeutics-receives-orphan-drug-designation-japan-dyne-251-duchenne-muscular</guid>
<pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
<description>- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late</description>
</item>
</channel>
</rss>